Literature DB >> 17990793

Exploring the native human antibody repertoire to create antiviral therapeutics.

S K Dessain1, S P Adekar, J D Berry.   

Abstract

Native human antibodies are defined as those that arise naturally as the result of the functioning of an intact human immune system. The utility of native antibodies for the treatment of human viral diseases has been established through experience with hyperimmune human globulins. Native antibodies, as a class, differ in some respects from those obtained by recombinant library methods (phage or transgenic mouse) and possess distinct properties that may make them ideal therapeutics for human viral diseases. Methods for cloning native human antibodies have been beset by technical problems, yet many antibodies specific for viral antigens have been cloned. In the present review, we discuss native human antibodies and ongoing improvements in cloning methods that should facilitate the creation of novel, potent antiviral therapeutics obtained from the native human antibody repertoire.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17990793      PMCID: PMC7121815          DOI: 10.1007/978-3-540-72146-8_6

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  185 in total

1.  Characterization of human monoclonal antibodies directed against hepatitis B surface antigen.

Authors:  P H Ehrlich; Z A Moustafa; J C Justice; K E Harfeldt; R L Kelley; L Ostberg
Journal:  Hum Antibodies Hybridomas       Date:  1992-01

2.  Comparative phenotypic analysis of available human hybridoma fusion partners.

Authors:  D Kozbor; J C Roder; M E Sierzega; S P Cole; C M Croce
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  The selection and characterization of human monoclonal antibodies to human cytomegalovirus.

Authors:  M J Redmond; M Leyritz-Wills; L Winger; D G Scraba
Journal:  J Virol Methods       Date:  1986-08       Impact factor: 2.014

4.  Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

Authors:  D K Shay; R C Holman; G E Roosevelt; M J Clarke; L J Anderson
Journal:  J Infect Dis       Date:  2000-11-10       Impact factor: 5.226

5.  Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin.

Authors:  A Moudgil; H Shidban; C C Nast; A Bagga; S Aswad; S L Graham; R Mendez; S C Jordan
Journal:  Transplantation       Date:  1997-12-27       Impact factor: 4.939

6.  High efficiency creation of human monoclonal antibody-producing hybridomas.

Authors:  Scott K Dessain; Sharad P Adekar; Jennifer B Stevens; Katherine A Carpenter; Maria L Skorski; Barry L Barnoski; Richard A Goldsby; Robert A Weinberg
Journal:  J Immunol Methods       Date:  2004-08       Impact factor: 2.303

7.  Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6.

Authors:  J F Harris; R G Hawley; T S Hawley; G C Crawford-Sharpe
Journal:  J Immunol Methods       Date:  1992-04-08       Impact factor: 2.303

8.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

9.  Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia.

Authors:  J C Goldsmith; N Eller; M Mikolajczyk; J Manischewitz; H Golding; D E Scott
Journal:  Vox Sang       Date:  2004-02       Impact factor: 2.144

10.  Generation of human monoclonal antibodies reactive with human mammary carcinoma cells.

Authors:  J Schlom; D Wunderlich; Y A Teramoto
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

View more
  3 in total

1.  Discovery of high affinity anti-ricin antibodies by B cell receptor sequencing and by yeast display of combinatorial VH:VL libraries from immunized animals.

Authors:  Bo Wang; Chang-Han Lee; Erik L Johnson; Christien A Kluwe; Josephine C Cunningham; Hidetaka Tanno; Richard M Crooks; George Georgiou; Andrew D Ellington
Journal:  MAbs       Date:  2016-05-25       Impact factor: 5.857

Review 2.  Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

Authors:  Patrick J McEnaney; Christopher G Parker; Andrew X Zhang; David A Spiegel
Journal:  ACS Chem Biol       Date:  2012-07-03       Impact factor: 5.100

3.  Prophylaxis and therapy for Chikungunya virus infection.

Authors:  Thérèse Couderc; Nassirah Khandoudi; Marc Grandadam; Catherine Visse; Nicolas Gangneux; Sébastien Bagot; Jean-François Prost; Marc Lecuit
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.